Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression.
2/5 보강
TL;DR
A hypoxia-responsive ATRA-phospholipid conjugate platform enables functional CSC priming and improved combination chemotherapy, offering a promising strategy for microenvironment-activated modulation of CSC-associated chemoresistance in metastatic breast cancer.
OpenAlex 토픽 ·
Retinoids in leukemia and cellular processes
Nanoplatforms for cancer theranostics
RNA Interference and Gene Delivery
A hypoxia-responsive ATRA-phospholipid conjugate platform enables functional CSC priming and improved combination chemotherapy, offering a promising strategy for microenvironment-activated modulation
APA
Chunlin Li, Di Liu, et al. (2026). Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression.. Molecular pharmaceutics, 23(4), 2340-2349. https://doi.org/10.1021/acs.molpharmaceut.5c01284
MLA
Chunlin Li, et al.. "Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression.." Molecular pharmaceutics, vol. 23, no. 4, 2026, pp. 2340-2349.
PMID
41725206 ↗
Abstract 한글 요약
Cancer stem-like cells (CSCs) are a key driving factor of tumor heterogeneity, metastasis, and chemoresistance. All-trans retinoic acid (ATRA) shows strong potential for inducing CSC differentiation and reducing stemness; however, its clinical translation is limited by the lack of effective targeting and favorable biodistribution under physiological conditions. Here, we report a hypoxia-responsive ATRA-phospholipid conjugate (RAPC) as a delivery and differentiation-priming strategy, enabling the fabrication of ATRA-loaded liposomes (ATRA@Lip) with high drug loading and microenvironment-activated release. RAPC was synthesized via a modular route incorporating an azobenzene-based hypoxia-cleavable linker between ATRA and a phosphatidylcholine analog. By coassembling RAPC with cholesterol and phospholipid, stable liposomes were obtained with a maximal ATRA loading of 17 wt % at 50 mol % RAPC content. Under normoxia, ATRA@Lip exhibited minimal leakage, whereas hypoxic conditions triggered rapid azo bond cleavage and accelerated ATRA release. Functionally, hypoxia-triggered ATRA@Lip promoted CSC differentiation and enhanced the chemosensitivity of breast cancer cells to albumin-bound paclitaxel (Nab-PTX) in vitro. Collectively, this hypoxia-responsive lipid-drug conjugate platform enables functional CSC priming and improved combination chemotherapy, offering a promising strategy for microenvironment-activated modulation of CSC-associated chemoresistance in metastatic breast cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Combination therapy for colorectal cancer with anti-PD-L1 and cancer vaccine: A multiscale mathematical model of tumor-immune interactions.
- Concurrent MLL-AF4 infant ALL in monozygotic twins: a case report.
- Adaptive and migration-enhanced tree seed algorithm for multi-threshold CT image segmentation and lung cancer recognition.
- Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
- Interaction Effects Between Tongue-Rolling Behavior and Chronic Stress on Plasma Immune-Inflammatory Indicators, Milk Protein Composition, and Milk Proteome in Dairy Cows.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.